RESCEU project aims to develop robust evidence on RSV disease burden & economic impact. It has received funding from IMI2 JU, GA N 116019 - H2020 R&I & EFPIA
Joined November 2015
- Tweets 429
- Following 189
- Followers 557
- Likes 167
108 Photos and videos
Pinned Tweet
29 Mar 2022
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking JU and others. Any related tweets reflect only the views of the author.
2
22 Mar 2023
📣 New @RESCEU #paper
👉For the first time, costs and health-related quality of life (HRQoL) effects associated with RSV in healthy term infants and their caregivers in a community setting in four European countries have been evaluated.
@promise_IMI @IHIEurope @zhuxinmmm
1
3
3
1,969
22 Mar 2023
Our research highlights the significant cost and HRQoL losses associated with RSV. These findings can help quantify the disease burden of RSV and inform future decision-making regarding interventions to protect young children from this disease.
1
208
22 Mar 2023
Read the ‘Vaccine’ #journal #article from @ElsevierConnect in full here: sciencedirect.com/science/ar…
@Promise_IMI @IHIEurope
174
RESCEU Project retweeted
24 Feb 2023
.@BeutelsPhilippe of University of Antwerp closes the health economics session of #RSVVW23 by presenting insights from the @RESCEUproject @IHIEurope @ReSViNET
1
2
13
481
RESCEU Project retweeted
22 Feb 2023
Brenda is part of the @RESCEUproject and @PROMISE_IMI Patient Advisory Board and is involved in #RSV research and awareness raising 👏
1
3
14
414
9 Feb 2023
📣 New @RESCEU #paper on #RSV monoclonal antibody and maternal immunization in 6 European countries suggests seasonal programme with or without catch-up could be cost-effective or even cost-saving.
@Promise_IMI @IHIEurope
👇Follow the 🧵 #Thread for key results:
1/6
9
2
11
1,940
9 Feb 2023
The choice between a maternal immunization or monoclonal antibodies depends on the level and duration of protection, price, availability and age-specific RSV-attributable hospitalizations in very young children, which should be based on the latest available evidence.
1
2
159
9 Feb 2023
6/6
📖 Read the ‘Vaccine’ #journal #article from @ElsevierConnect in full here:
sciencedirect.com/science/ar…
@Promise_IMI @IHIEurope
2
144
RESCEU Project retweeted
2 Feb 2023
Another @RESCEUproject publication 💪
Congratulations to all involved, including @JJGTvanSummeren
sciencedirect.com/science/ar…
2
15
780
23 Jan 2023
1/5
📣 #NewPaper by @RESCEUproject #scientists!
📖Read the latest publication in @ElsevierConnect on the cost-effectiveness of #RSV (Respiratory Syncytial Virus) interventions in children.
@PROMISE_IMI @IHIEurope @WHO_Europe_VPI
👇Follow the🧵#Thread for key results:
1
3
8
1,268
23 Jan 2023
4/5
But we found important differences on non-medically attended symptomatic RSV burden and waning immunity. These aspects need more attention in future trials and analyses.
👇
1
1
181
23 Jan 2023
5/5
📖 Read the ‘Value in Health’ #journal #article from @ElsevierConnect in full here:
authors.elsevier.com/a/1gPji…
@PROMISE_IMI @IHIEurope
138
RESCEU Project retweeted
29 Dec 2022
#RSV is in the headlines, with cases rising across Europe. IMI project @RESCEUproject shed new light on the burden of RSV, knowledge that could improve how the disease is managed, treated (and hopefully prevented) in the future.
bit.ly/3xA38sb
#RespiratorySyncitialVirus
2
3
458